Form 4: United Therapeutics CEO Sells Shares Under 10b5-1 Plan
Insider Transaction Report
United Therapeutics CEO Martine A. Rothblatt exercised stock options and sold 9,500 shares of common stock as part of a pre-arranged 10b5-1 trading plan.
Summary
- Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp (UTHR), exercised 9,500 stock options at an exercise price of $146.03 per share.
- Concurrently, 9,500 shares of common stock were sold in multiple transactions on March 4, 2026, at weighted average prices ranging from $486.4229 to $497.05.
- These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025.
- Following these transactions, Rothblatt directly beneficially owns 130 shares of common stock.
- Indirect beneficial ownership includes 166 shares by spouse and 639,193 shares held across various family trusts.
- Rothblatt retains 211,500 unexercised stock options.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event. While insider selling can sometimes be a negative signal, the execution under a pre-arranged 10b5-1 plan mitigates concerns about opportunistic selling based on undisclosed information.
Positives
- The transaction was executed under a pre-arranged 10b5-1 trading plan, indicating a planned, non-discretionary sale rather than a reaction to new information.
Negatives
- The CEO sold a significant number of shares, which can sometimes be perceived negatively by investors, even if pre-planned.
Future Outlook
The pre-arranged 10b5-1 trading plan is set to continue until the earlier of the exercise of 1,734,410 stock options (expiring March 17, 2027) or December 31, 2026.
Industry Context
StockSavvy.ai notes that insider sales, particularly by top executives, are common under Rule 10b5-1 plans in the biotechnology and pharmaceutical sectors, often used for personal financial planning and diversification rather than signaling a change in company fundamentals.
Stakeholder Impact
- Shareholders: The sale of shares by the CEO could be perceived as a slight negative, but the pre-planned nature under a 10b5-1 plan generally reduces concerns about its implications for company performance.
Next Steps
- The 10b5-1 trading plan will continue, involving the potential exercise of up to 1,734,410 additional stock options.
Key Dates
| Date | Description |
|---|---|
| 2020-03-15 | Date stock options became exercisable. |
| 2025-11-07 | Date the 10b5-1 trading plan was adopted by the reporting person. |
| 2026-03-04 | Date of stock option exercise and subsequent sale of common stock. |
| 2026-03-05 | Date of filing of the Form 4. |
| 2026-12-31 | Earliest potential end date for the 10b5-1 trading plan. |
| 2027-03-15 | Expiration date of the exercised stock options. |
| 2027-03-17 | Expiration date of the remaining 1,734,410 stock options under the 10b5-1 plan. |
Recommendation
holdThe Form 4 filing details a pre-planned insider sale by the CEO, which is a routine event for executive compensation and personal financial management. It does not provide new fundamental information about United Therapeutics' operations, financial health, or future prospects that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as this filing alone does not alter the investment thesis.
Keywords
United Therapeutics, UTHR, Martine A. Rothblatt, Insider Trading, Form 4, Stock Options, Share Sale, 10b5-1 Plan, CEO, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.